Repligen
RGEN----
Q1 FY2026 EarningsRepligen (RGEN) announced a $1.5B acquisition of BioLife Solutions (BLFS) to scale its cell therapy bioprocessing capabilities. Preliminary Q2 2026 revenue grew 12% YoY (13% organic), with expectations for significant margin expansion. The transaction is projected to be accretive to adjusted EPS by $0.05 in Year 1 and $0.25 in Year 2, supported by $30M in projected annual synergies. BioLife reported preliminary Q2 revenue of $28.5M, up 21% YoY, driven by its high-margin biopreservation media business.
Financial report interval: 2025.12.31 - 2026.03.31
Preview: Repligen(RGEN) predict that the Revenue is 194.26 M (+14.83%), Beat estimate;the EBIT is 29.9 M (+27.77%), Beat estimate;the EPS is 0.15 (+50%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.19B14.83%
0.19B13.70%
+0.00B1.13%
EBITExceed expectations
0.03B27.77%
0.02B2.99%
+0.01B24.78%
EPSMiss expectations
0.1550.00%
0.182582.50%
-0.032532.50%
Upcoming earnings report - FY2026 Q2 Earning Release
Available dateJul 28, 2026
Estimate Revenue201.4 M
Estimate EBIT28.21 M
Estimate EPS0.28
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf